SFX-01 positive update in bowel cancer models
27/02/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240227:nRSa5105Ea&default-theme=true
RNS Number : 5105E Evgen Pharma PLC 27 February 2024
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Positive update on SFX-01 on studies in bowel cancer models
Further evidence of SFX-01 activity in models of a major cancer
Alderley Park, UK - 27 February 2024: Evgen Pharma plc (AIM: EVG), the
clinical stage drug development company developing sulforaphane-based
medicines for the treatment of multiple diseases, announces that the
laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and
Professor Duxin Sun at the University of Michigan, USA have observed activity
of SFX-01 in models of colon cancer.
The in vitro and in vivo studies, funded by the USA National Cancer Institute
and the University of Michigan will be generating data continuously throughout
the project.
According to one of the lead investigators, Professor Chen of the Division of
Hematology and Oncology, Department of Internal Medicine at the University of
Michigan Medical School:
"We have shown preliminary signs of anti-tumour activity of SFX-01 in
organoids derived from human tumours."
Dr Huw Jones, CEO of Evgen Pharma said:
"These early data from our collaborators in the USA show encouraging evidence
of activity of SFX-01 in another significant cancer. Colorectal or bowel
cancer is the third most common cancer worldwide accounting for around one in
ten of all cancer diagnoses and a cause of significant morbidity and
mortality. We look forward to continuing to work with Prof Chen and colleagues
to learn more about SFX-01 in this setting."
-Ends-
Enquiries
Evgen Pharma plc +44 207 457 2020
Dr Huw Jones, CEO enquiries@evgen.com
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
Cavendish Capital Markets (NOMAD and Broker) +44 20 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Nigel Birks (ECM)
Instinctif Partners +44 207 457 2020
Evgen@Instinctif.com
Melanie Toyne-Sewell / Jack Kincade
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing
sulforaphane based medicines for the treatment of multiple diseases. The
Company's core technology is Sulforadex®, a method for synthesising and
stabilising the highly biologically active compound sulforaphane and novel
proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin and has undergone clinical trials for
oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b
study of the Company's new enteric coated tablet formulation. The FDA has
granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be
investigated initially in this indication as an investigator sponsored study
in the Netherlands.
The Company also has a wide number of collaborations with leading academic
centres in the UK, Europe and the US as part of the continuing strategy to
build the scientific data for the compound. Recently, Evgen completed an
out-licensing transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum disorder. The
deal, if successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol EVG.
For further information, please visit: www.evgen.com (http://www.evgen.com)
.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUNUBRSKUUUAR